As previously noted, increased excitability in tauopathies may be driven in part by decreased KCC2 expression as introduction of FTD-associated tau mutations decrease KCC2 levels in a human neuronal model (García-León et al., 2018). This evidence concerns the gene MAPT and frontotemporal dementia.